Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Adbry (Tralokinumab-ldrm) is indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. It can be used with or without topical corticosteroids.
• The information comes from 17 systematic reviews and meta-analyses, focusing on direct outcomes such as efficacy, safety, and specific subpopulation considerations where available.
• In terms of efficacy comparison to other drugs like Dupilumab and JAK inhibitors (Janus kinase inhibitors), tralokinumab shows similar effectiveness when combined with topical corticosteroids. However, JAK inhibitors were generally associated with higher efficacy but also a higher incidence of Herpes zoster.
• Safety comparisons reveal that tralokinumab has no significant difference observed in the incidence of overall adverse events compared to placebo. Yet, it was found safer than JAK inhibitors which showed a dose-dependent increase in Herpes zoster occurrence.
• Tralokinumab was associated with an increased incidence of conjunctivitis compared to placebo; however, this condition was mostly mild or moderate and transient - similar findings were noted for Dupilumab and other IL13-inhibitors.
• Compared to systemic treatments like JAK inhibitors known for harmful outcomes due to increased adverse events, both tralokinumab-ldrm (Adbry) & dupilumab have been listed among biologics having favorable safety profiles despite modestly increasing the risk towards conjunctivitis.
• The studies predominantly focused on adult populations suffering from moderate-to-severe AD, indicating sustained/improved efficiency/safety over time, including up till 52 weeks into treatment.
• Few studies addressed pediatric use directly, thus highlighting the need for further research, especially concerning long-term safety/efficiency aspects related to biologics usage such as tralokinumab within children.